News Results for GlaxoSmithKline (GSK)

Oil giants BP (BP.) and Royal Dutch Shell (RDSB) boosted the FTSE 100 thanks to stable oil prices. Brent crude oil advanced 0.6% to $55.84 per barrel. Gold and copper were stable at $1,305 per...

GlaxoSmithKline has announced that the US Food and Drug Administration's vaccines and related biological products advisory committee has voted unanimously that the data support the efficacy and...

Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1570p (from 1750p). Story provided by StockMarketWire.com

GlaxoSmithKline and Innoviva have announced that positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at the European...

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1725p (from 1775p). Story provided by StockMarketWire.com

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1750p (from 1900p). Story provided by StockMarketWire.com

Berenberg today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1835p (from 1885p). Story provided by StockMarketWire.com

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1610p (from 1720p). Story provided by StockMarketWire.com

Urs Rohner, Non Executive Director, bought 567 shares in the company on the 26th July 2017 at a price of 1599.00p. The Director now holds 4,350 shares representing 0.00% of the shares in issue....

Sir Roy Anderson, Non Executive Director, bought 567 shares in the company on the 26th July 2017 at a price of 1599.00p. The Director now holds 234,347 shares representing 0.00% of the shares in...

Manvinder Banga, Non Executive Director, bought 2,267 shares in the company on the 26th July 2017 at a price of 1599.00p. The Director now holds 11,392 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 449 shares in the company on the 26th July 2017 at a price of 1599.00p. The Director now holds 1,131 shares representing 0.00% of the shares in...

Sir Philip Hampton, Chairman, bought 2,736 shares in the company on the 26th July 2017 at a price of 1599.00p. The Director now holds 27,212 shares representing 0.00% of the shares in issue....

ViiV Healthcare, owned by GlaxoSmithKline, has announced positive interim results from the NEAT 02 study of more than 400 patients with HIV and high cardiovascular risk. The study was conducted by...

ViiV Healthcare, owned by GlaxoSmithKline, has announced positive interim results from the DAWNING study, modified to allow patients the opportunity to receive dolutegravir-based regimens. This is...

Bryan Garnier today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1790p (from 1750p). Story provided by StockMarketWire.com

GlaxoSmithKline and Innoviva has announced that they have submitted a filing to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone...

GlaxoSmithKline has announced the appointment of Dr Laurie Glimcher as a Non-Executive Director and has been deemed a Scientific and Medical Expert. The Group confirmed that Dr Glimcher will join...

Housebuilders rallied following an 'excellent' trading performance at Persimmon (PSN). The UK housebuilder said it had seen strong momentum moving into the second half of the year and highlighted...

Citigroup today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to neutral (from buy) and set its price target at 1700p. Story provided by StockMarketWire.com

GlaxoSmithKline has announced that the Company has started a phase III study with mepolizumab, an interleukin 5 (IL-5) antagonist, in patients with severe bilateral nasal polyps. It said the study...

Investor sentiment remained subdued as insurance and utility stocks weighed on the FTSE. Direct Line (DLG) fell 1.9% to 356.9p, RSA Insurance (RSA) ticked 1.8% lower to 617p. Severn Trent (SVT)...

GSK has confirmed that it will be presenting new results from a clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or older,...

GlaxoSmithKline has confirmed that Luke Miels would start his appointment as president, global pharmaceuticals, on 4 September having reached an agreement with AstraZeneca. At 8:39am: (LON:GSK)...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1900p (from 1800p). Story provided by StockMarketWire.com

Beaufort Securities today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2000p (from 1750p). Story provided by StockMarketWire.com

Goldman Sachs today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1900p. Story provided by StockMarketWire.com

Berenberg has upgraded its recommendation on GlaxoSmithKline (LON:GSK) believing long-term value is emerging and that risks are now skewed to the upside at a group level, despite its HIV business,...

Berenberg today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to buy (from hold) and raised its price target to 1885p (from 1850p). Story provided by StockMarketWire.com

GlaxoSmithKline has presented data from a post-hoc analysis of the phase IIIb MUSCA study in which first-in-class biologic Nucala (mepolizumab) consistently improved health-related quality of life...

GlaxoSmithKline and Innoviva have announced positive results from the Salford Lung Study (SLS) in asthma. The study was carried out amongst 4,233 patients treated by their own General Practitioner...

GlaxoSmithKline has confirmed that all resolutions proposed at its annual general meeting yesterday were passed by shareholders. At 8:56am: (LON:GSK) GlaxoSmithKline PLC share price was -1.25p...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1700p (from 1720p). Story provided by StockMarketWire.com

GlaxoSmithKline has reported sales growth in the first quarter of 19% AER, 5% CER to £7.4bn, which it said was driven by continued momentum and growth in all three businesses. Pharmaceuticals...

Emma Walmsley, Executive Director, has re-invested 5,666 shares in the company on the 18th April 2017 at a price of 1647.00p. The Director now holds 20,128 shares representing 0.00% of the shares...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1800p (from 1850p). Story provided by StockMarketWire.com

Japan Vaccine Co - a joint venture of GlaxoSmithKline and Daiichi Sankyo Co - has submitted a new drug application in Japan seeking approval for the candidate shingles vaccine, Shingrix, for the...

GlaxoSmithKline has announced that it will be making a number of changes to the format and content of its financial reports from Q1, 2017. A summary of the changes are as follows: - Core results...

GlaxoSmithKline has confirmed that the Company's Annual General Meeting will be held on 4 May 2017. At 1:13pm: (LON:GSK) GlaxoSmithKline PLC share price was +7.25p at 1685.75p Story provided...

Societe Generale today reaffirms its sell investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1300p. Story provided by StockMarketWire.com

Berenberg today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1890p (from 1850p). Story provided by StockMarketWire.com

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1900p (from 1800p). Story provided by StockMarketWire.com

Barclays Capital today initiates coverage of GlaxoSmithKline PLC (LON:GSK) with a equal weight investment rating and price target of 1550p. Story provided by StockMarketWire.com

GlaxoSmithKline has said that its MUSCA study shows Nucala (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype. The...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1800p (from 1780p). Story provided by StockMarketWire.com

Andrew Witty, Chief Executive Officer, has transferred out 63,441 shares in the company on the 10th February 2017 at a price of 0.00p. The Director now holds 541,488 shares. NOTE: Gifted to...

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1670p (from 1600p). Story provided by StockMarketWire.com

Beaufort Securities today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1750p. Story provided by StockMarketWire.com

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1720p (from 1800p). Story provided by StockMarketWire.com

GlaxoSmithKline has reported an increase in Group sales of 6% (5% pro-forma) to £27.9bn for the year ended 31 December 2016, with 2016 core EPS up 12% (CER) at 102.4p. However, GSK said it faces...

Goldman Sachs today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1850p (from 1800p). Story provided by StockMarketWire.com

Dr Patrick Vallance, Executive Director, has re-invested 370 shares in the company on the 16th January 2017 at a price of 1597.00p. The Director now holds 9,896 shares representing 0.00% of the...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1780p (from 1750p). Story provided by StockMarketWire.com

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1800p (from 1760p). Story provided by StockMarketWire.com

Simon Dingemans, Financial Director, has re-invested 122 shares in the company on the 12th January 2017 at a price of 1571.49p. The Director now holds 469,370 shares. Story provided by...

Dr Moncef Slaoui, Executive Director, has re-invested 1,694 shares in the company on the 12th January 2017 at a price of 1571.49p. The Director now holds 130,686 shares representing 0.00% of the...

Emma Walmsley, Executive Director, has re-invested 489 shares in the company on the 12th January 2017 at a price of 1570.75p. The Director now holds 8,730 shares representing 0.00% of the shares in...

Dr Patrick Vallance, Executive Director, has re-invested 245 shares in the company on the 12th January 2017 at a price of 1570.75p. The Director now holds 288 shares representing 0.00% of the...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1750p (from 1700p). Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1600p (from 1800p). Story provided by StockMarketWire.com

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has started a phase III study to evaluate long-acting injectable...

GlaxoSmithKline announced the creation of a new board committee and a number of changes to the membership of the board and its committees, which will all take effect from 1 January 2017. A new...

GlaxoSmithKline and Innoviva have announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1700p (from 1850p). Story provided by StockMarketWire.com

Simon Dingemans, Financial Director, exercised 216 shares in the company on the 1st December 2016 at a price of 1247.00p. The Director now holds 469,226 shares. Story provided by...

GlaxoSmithKline and Innoviva have announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone...

GlaxoSmithKline and Innoviva, have announced that the Japanese Ministry of Health, Labour and Welfare has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) for the relief of...

GlaxoSmithKline has announced the regulatory submission of a Marketing Authorisation Application to the European Medicines Agency seeking approval for its candidate shingles vaccine, Shingrix, for...

GlaxoSmithKline says both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study investigating the efficacy and safety of mepolizumab, an IL-5 antagonist, in...

Story provided by StockMarketWire.com

London stocks opened the session mixed -- the blue-chip ladder up and the mid-cap down -- with big-ticket mining and oil companies making gains as the price of gold and crude oil improving. At...

GlaxoSmithKline has filed a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced the start of two phase III studies designed to evaluate an...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1850p (from 1950p). Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1800p (from 1900p). Story provided by StockMarketWire.com

Andrew Witty, Chief Executive Officer, sold 10,000 shares in the company on the 27th October 2016 at a price of 1636.50p. The Director now holds 574,786 shares. Story provided by...

Natixis today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1750p. Story provided by StockMarketWire.com

GlaxoSmithKline has submitted a biologics licence application for its candidate shingles vaccine, Shingrix, to the United States Food and Drug Administration, seeking approval for the prevention of...

Story provided by StockMarketWire.com

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1800p (from 1440p). Story provided by StockMarketWire.com

Investec today initiates coverage of GlaxoSmithKline PLC (LON:GSK) with a buy investment rating and price target of 1925p. Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1667p. Story provided by StockMarketWire.com

Simon Dingemans, Financial Director, has re-invested 1,698 shares in the company on the 13th October 2016 at a price of 1700.00p. The Director now holds 461,891 shares. Story provided by...

Emma Walmsley, Director, has re-invested 1,224 shares in the company on the 13th October 2016 at a price of 1700.00p. The Director now holds 2,444 shares representing 0.00% of the shares in issue....

Andrew Witty, Chief Executive Officer, has re-invested 3,156 shares in the company on the 18th October 2016 at a price of 1700.00p. The Director now holds 567,850 shares. Story provided by...

Andrew Witty, Chief Executive Officer, has re-invested 3,156 shares in the company on the 18th October 2016 at a price of 1700.00p. The Director now holds 567,850 shares. Story provided by...

Andrew Witty, Chief Executive Officer, has re-invested 3,156 shares in the company on the 18th October 2016 at a price of 1700.00p. The Director now holds 567,850 shares. Story provided by...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1950p (from 1900p). Story provided by StockMarketWire.com

GlaxoSmithKline has confirmed a US regulatory submission for sirukumab in rheumatoid arthritis. GSK says a biologics licence application has been submitted to the US Food and Drug Administration...

The FTSE 100 continued to gain positive momentum despite the pound weakening 0.5% against both the US dollar and Euro. The blue chip index closed 0.2% higher at 6,830 and the FTSE 250 was flat at...

The FTSE 100 was 0.5% higher at 6,849 as investors were relaxed ahead of upcoming UK public sector borrowing and Japanese trade data. Tesco (TCSO) nudged 1.3% higher after losing less market share...

GlaxoSmithKline has appointed Emma Walmsle as chief executive designate. Walmsley, who is currently CEO of GSK's consumer healthcare division, will take over from Andrew Witty when he retires on 31...

Societe Generale today reaffirms its sell investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1320p. Story provided by StockMarketWire.com

Exane BNP Paribas today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to underperform (from neutral) and set its price target at 1520p. Story provided by StockMarketWire.com

Liberum Capital today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1900p. Story provided by StockMarketWire.com

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1900p (from 2000p). Story provided by StockMarketWire.com

Andrew Witty, Chief Executive Officer, bought 8 shares in the company on the 9th September 2016 at a price of 1615.50p. The Director now holds 555,654 shares. NOTE: Awarded 8 matching shares....

Simon Dingemans, Financial Director, bought 8 shares in the company on the 9th September 2016 at a price of 1615.50p. The Director now holds 460,075 shares. NOTE: Awarded 8 matching shares. Story...